Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JNJ-79635322 |
Trade Name | |
Synonyms | JNJ 79635322|JNJ79635322 |
Drug Descriptions |
JNJ-79635322 is a trispecific antibody that targets TNFRSF17 (BCMA) and GPRC5D on tumor cells, and CD3 on T-cells, which potentially induces cytotoxicity against tumor cells (Blood (2023) 142 (Supplement 1): 456). |
DrugClasses | CD3 Antibody 103 TNFRSF17 Antibody 21 |
CAS Registry Number | NA |
NCIT ID | C199288 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Daratumumab + JNJ-79635322 | Daratumumab JNJ-79635322 | 0 | 1 |
JNJ-79635322 | JNJ-79635322 | 0 | 1 |
JNJ-79635322 + Pomalidomide | JNJ-79635322 Pomalidomide | 0 | 1 |